Despite AAT deficiency being extensively studied and exogenous AAT administered as a therapy to AAT-deficient emphysema subjects, little is known about the potential long-term effects of AAT signaling on T1DM patients. The gene discussed is SERPINA1; the disease is alpha 1-antitrypsin deficiency.